The Acomplia Product Manager at Sanofi-Aventis must be cursing their luck! Nigel Brooksby, Sanofi-Aventis UK's managing director has been named as the ABPI's next president.
Brooksby will take over from the current ABPI president, Vincent Lawton (who has his own problems....scroll down a couple of stories), of Merck Sharpe & Dohme, in April next year, and will serve for two years.
Brooksby will work alongside ABPI director general Richard Barker in promoting the interests of the UK pharmaceutical industry in its domestic market and within a European context.
"With health services across Europe facing difficult times, it is essential that the pharmaceutical industry works in close co-operation with the government to ensure patients get the best possible treatment," said Brooksby.
Formerly head of Sanofi-Synthelabo in the UK, Brooksby oversaw its merger with Aventis in 2004 and was appointed the managing director of the new company, with responsibility for 3,200 staff.
And why is the Acomplia PM cursing, you ask? Well, they must now try harder to ensure its launch (coming soon, aka - rimonabant) does not break the ABPI Code of Practice for promotion. It wouldn't look too good if it did, would it?
No comments:
Post a Comment